Archived Monthly Oncology Tumor Boards: Management of Early-Stage Non-Small Cell Lung Cancer
Health care providers need to know about the recent updates to the NCCN Guidelines for Non-Small Cell Lung Cancer to provide the best care for their patients with NSCLC, including adverse reactions that may occur with use of the new neoadjuvant and adjuvant systemic therapy regimens.
Category
  • Lung Cancers
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Unlocking the Potential of Neoadjuvant and Adjuvant Immunotherapy in Resectable NSCLC: The Role of Checkpoint Inhibitors
The goal of this initiative is to provide education to assist clinicians in providing appropriate care for patients with non-small cell lung cancer (NSCLC) through a greater understanding of the significance of biomarker testing to predict treatment response, the role of PD-1/PD-L1 inhibitors in
Category
  • Lung Cancers
Format
  • Recorded Webcast
Credits
  • 1.75 AAPA Category 1 CME credit
  • 1.75 AMA PRA Category 1 Credit™
  • 1.75 ANCC contact hours
  • 1.75 Participation
Updates in the Management of Small Cell Lung Cancer
For many years, platinum plus etoposide regimens had been recommended for patients with extensive stage small cell lung cancer (SCLC); however, the preferred regimens for extensive stage SCLC now include immune checkpoint inhibitors, either atezolizumab or durvalumab, plus platinum plus etoposide.
Category
  • Lung Cancers
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
New Targeted Therapies for Metastatic Non-Small Cell Lung Cancer
Clinicians need to be aware of the most recent recommendations about biomarker testing and the appropriate use of new targeted therapies (including sequencing these therapies, assessing and managing side effects from these therapies), so they can select the most appropriate therapy for their patients with metastatic NSCLC.
Category
  • Lung Cancers
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation